Preclinical studies have demonstrated the potential of IRAP inhibitors as cognitive enhancers and for treating neurodegenerative conditions such as Alzheimer's disease, which are characterized by progressive cognitive and memory decline. Here, LNPEP is linked to Alzheimer disease.